Infliximab, an anti-TNF monoclonal antibody, has been an adequate therapy for Crohn’s disease worldwide, and its effect is based on neutralizing the bioactive TNF in the intestinal mucosa, as well as it can promote apoptotic T-cell death [10]. The gene discussed is TNF; the disease is Crohn disease.